Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Sep 17:11:5909-5915.
doi: 10.2147/OTT.S101333. eCollection 2018.

Therapy-related myeloid neoplasms: clinical perspectives

Luana Fianchi  1 , Marianna Criscuolo  1 , Emiliano Fabiani  2 , Giulia Falconi  2 , Alessio Maria Edoardo Maraglino  1 , Maria Teresa Voso  2 , Livio Pagano  1
Affiliations
Review

Therapy-related myeloid neoplasms: clinical perspectives

Luana Fianchi et al. Onco Targets Ther. .

Abstract

Therapy-related myeloid neoplasms (t-MNs) are a complication of cytotoxic treatment for primary tumors and autoimmune diseases. t-MNs result from a complex interaction between individual predisposition and exposition to toxic agents. Some different biological and clinical characteristics can be recognized according to the type of anticancer drug. Compared to de novo myeloid neoplasms, prognosis of t-MN is dismal. Age and karyotype are the most important prognostic factors for t-MN, which should be treated with frontline chemotherapy treatments that are appropriate for patients with myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) with similar disease characteristics. Allogeneic stem cell transplantation should be considered particularly for unfavorable karyotypes and younger patients with aggressive disease.

Keywords: leukemia; prognosis; secondary leukemia; secondary myelodysplastic syndrome; therapy-related myeloid neoplasm.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

References

    1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–951. - PubMed
    1. Morton LM, Dores GM, Tucker MA, et al. Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975–2008. Blood. 2013;121(15):2996–3004. - PMC - PubMed
    1. Greim H, Kaden DA, Larson RA, et al. The bone marrow niche, stem cells, and leukemia: impact of drugs, chemicals, and the environment. Ann N Y Acad Sci. 2014;1310(1):7–31. - PMC - PubMed
    1. Kayser S, Döhner K, Krauter J, et al. German-Austrian AMLSG The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood. 2011;117(7):2137–2145. - PubMed
    1. Hulegårdh E, Nilsson C, Lazarevic V, et al. Characterization and prognostic features of secondary acute myeloid leukemia (AML) in a population based setting: a report from the Swedish acute leukemia registry. Am J Hematol. 2015;90(3):208–214. - PubMed